Other reasons for a treatment switch in our cohort were adverse effects and infusion-related side effects: For inotersen, adverse effects observed (glomerulonephritis and thrombocytopenia) align with safety findings from the NEURO-TTR trial, which reported three cases each of thrombocytopenia and glomerulonephritis [20]. The gene discussed is TTR; the disease is glomerulonephritis.